- Repatha - evolocumab, first in Europe registered inhibitors PCSK2015 | First Faculty of Medicine
- Treating hypercholesterolaemia with evolocumab +12018 | First Faculty of Medicine
- Fourier Study: Has it brought little or a lot of good? Or has it just failed to reach exaggerated expectations?2017 | First Faculty of Medicine
- PCSK-inhibitor in theory, in studies and in the real practice2019 | First Faculty of Medicine
- Evolocumab, proproteine convertase subtilisin/kexin type 9 inhibitor for intensive treatment of dyslipidemia2016 | Faculty of Medicine in Pilsen
- Biologická léčba hypercholesterolemie2017 | First Faculty of Medicine